Update on NHS National Portals Contracts

Induction Healthcare Group PLC
10 October 2023
 

Induction Healthcare Group PLC

("Induction", the "Company", or the "Group")

 

Update on NHS National Portals Contracts

 

Induction (AIM: INHC), a leading digital health platform driving transformation of healthcare systems, provides an update on recent contracts wins with the NHS.

 

Induction has recently signed three new patient portal development contracts totaling £1.4m:

 

·      North Central London ICS (covering three Trusts) worth £486,000 enabling patients, through the Zesty patient portal, to view their diagnostic appointment details as well as launch an Attend Anywhere video consultation.

 

·      Royal Free London worth £346,000 covering several patient portal projects including the use of Induction's Form Builder module for wait list validation and enhancing functionality for Patient Initiated Follow Up (PIFU), an initiative seen by the NHS as being vital in reducing the backlog. Induction will also be working with the Royal Free and other customers to be the first NHS-accredited portal to digitize maternity records for expectant mothers and ensure the records are accessible within Zesty.

 

·      South West London ICB worth £577,000 covering several patient portal projects which also includes the use of the Form Builder module for waitlist validation. These projects will also deepen Induction's bespoke integration with Oracle Health to enable data to be written back to the hospital system, reducing the data processing administrative burden on Trusts.

 

Induction CEO, Paul Tambeau, said: "These development and supply contracts demonstrate Induction's growing traction in the patient platform market as we work with the NHS to give patients more choice in how their care is managed. It also validates our strategy of integrating our Attend Anywhere video consultation and our Zesty patient portal platforms. These contracts also allow Induction to introduce new appointment types and to further deepen our technical integration with partners. We are also proud to be the first NHS-accredited portal provider in the UK to digitize maternity records and make it easier for expectant mothers to access their records.

 

Induction is currently negotiating additional contracts across the NHS and we look forward to providing further updates at the time of our Interim results which will be published on 7 November 2023.

 

 

Enquiries

 

Induction

Christopher Samler, Chair

Paul Tambeau, Chief Executive Officer

 

+44 (0)7712 194092

+44 (0)7983 104443





Singer Capital Markets (Nominated Adviser and Broker)

+44 (0)20 7496 3000

 

Philip Davies, Alaina Wong



 

About Induction - www.inductionhealthcare.com

Induction (AIM: INHC) delivers a suite of software solutions through a single integrated platform that transforms care delivery. Our system-wide applications help healthcare providers and administrators to deliver care at any stage remotely as well as face-to-face - giving the communities they serve greater flexibility, control and ease of access. Purpose-built for integration with leading Electronic Medical Record (EMR) platforms, our products offer immediate stand-alone value that becomes even greater when integrated with pre-existing systems.

 

Used at scale by national and regional healthcare systems, as well non-health government services, our applications are relied upon by hundreds of thousands of clinicians and millions of patients across almost every hospital in the British Isles.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100